A review of the antimicrobial activity of clavulanate

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 1, 2003, Pages 18-23

  Finlay, Jane ^a   Miller, Linda ^a   Poupard, James A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Clavulanate; Streptococcus pneumoniae; lactamase

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEFOTAXIME; CEFPIROME; CLAVULANIC ACID; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; SULBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN;

ANAEROBIC INFECTION; ANTIMICROBIAL ACTIVITY; AUTOLYSIS; BACTERIAL INFECTION; BACTERIUM CULTURE; CHLAMYDIA TRACHOMATIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR KILLING; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENICITY; PLASMID; POLYMORPHONUCLEAR CELL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0038262704     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg286     Document Type: Review

References (43)

1. Reading, C. & Cole, M. (1977). Clavulanate: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrobial Agents and Chemotherapy 11, 852-7.
2. Rolinson, G. N. (1994). A review of the microbiology of amoxycillin/clavulanate over the 15 year period 1978-1993. Journal of Chemotherapy 6, 283-318.
3. Todd, P. A. & Benfield, P. (1990). Amoxicillin/clavulanate. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39, 264-307.
4. Miller, L. A., Ratnam, K. & Payne, D. J. (2001). Lactamase-inhibitor combinations in the 21st century: current agents and new developments. Current Opinion in Pharmacology 1, 451-8.
5. Ball, P., Geddes, A. & Rolinson, G. N. (1997). Amoxycillin clavulanate: an assessment after 15 years of clinical application. Journal of Chemotherapy 9, 167-98.
6. Stokes, D. H., Slocombe, B. & Sutherland, R. (1989). Bactericidal effects of amoxycillin/clavulanate against Legionella pneumophila. Journal of Antimicrobial Chemotherapy 23, 43-51.
7. Stokes, D. H., Wilkinson, M. J., Tyler, J. et al. (1989). Bactericidal effects of amoxycillin/clavulanate against intracellular Legionella pneumophila in tissue culture studies. Journal of Antimicrobial Chemotherapy 23, 547-56.
8. Bowie, W. R. (1986). In vitro activity of clavulanate, amoxicillin, and ticarcillin against Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 29, 713-5.
9. Comber, K. R., Horton, R., Layte, S. J. et al. (1980). Augmentin: antibacterial activity in vitro and in vivo. In Augmentin: Clavulanate-Potentiated Amoxycillin. Proceedings of the First Symposium - 1980 (Rolinson, G. N. & Watson, A., Eds), pp. 19-38. Excerpta Medica, Amsterdam, The Netherlands.
10. Peters, G. & Pulverer, G. (1983). In vitro antibacterial activity of clavulanate-potentiated amoxycillin. In Augmentin: Clavulanate-Potentiated Amoxycillin. Proceedings of the European Symposium - 1982 (Croydon, E. A. P. & Michel, M. F., Eds), pp. 47-51. Excerpta Medica, Amsterdam, The Netherlands.
11. Smith, G. M., Abbott, K. H. & Sutherland, R. (1992). Bactericidal effects of co-amoxiclav (amoxycillin clavulanate) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat. Journal of Antimicrobial Chemotherapy 30, 525-34.
12. Smith, G. M., Abbott, K. H., Wilkinson, M. J. et al. (1991). Bactericidal effects of amoxycillin/clavulanate against a Legionella pneumophila pneumonia in the weanling rat. Journal of Antimicrobial Chemotherapy 27, 127-36.
13. Smith, G. M. & Sutherland, R. (1992). Activity of amoxycillin-clavulanate against Legionella pneumophila in vitro and in an experimental respiratory infection model. Journal of Hospital Infection 22, Suppl. A, 61-7.
14. Thorburn, C. E., Knott, S. J. & Edwards, D. I. (1998). In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance. Antimicrobial Agents and Chemotherapy 42, 1973-9.
15. Thorburn, C. E., Molesworth, S. J., Sutherland, R. et al. (1996). Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrobial Agents and Chemotherapy 40, 2796-801.
16. White, A. R., Boon, R. J., Masters, P. J. et al. (1983). Antibacterial activity of amoxycillin/clavulanate (Augmentin) in vitro. In Augmentin: Clavulanate-Potentiated Amoxycillin. Proceedings of the European Symposium - 1982. (Croydon, E. A. P. & Michel, M. F., Eds), pp. 21-39. Excerpta Medica, Amsterdam, The Netherlands.
17. Smith, G. M., Abbott, K. H., Wilkinson, M. J. et al. (1991). Bactericidal effects of ticarcillin-clavulanate against Legionella pneumophila pneumonia in immunocompromised weanling rats. Antimicrobial Agents and Chemotherapy 35, 1423-9.
18. Skov, R., Frimodt-Moller, N. & Espersen, F. (2002). In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime. APMIS 110, 559-64.
19. Mandell, L. A. (1999). Antibiotic therapy for community-acquired pneumonia. Clinics in Chest Medicine 20, 589-98, ix.
20. Butler, D. L., Gagnon, R. C., Miller, L. A. et al. (1999). Differences between the activity of penicillin, amoxycillin, and co-amoxiclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996. Journal of Antimicrobial Chemotherapy 43, 777-82.
21. Kays, M. B., Wood, K. K. & Miles, D. O. (1999). In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri. Pharmacotherapy 19, 1308-14.
22. Severin, A., Severina, E. & Tomasz, A. (1997). Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanate. Antimicrobial Agents and Chemotherapy 41, 504-10.
23. Cuffini, A. M., Tullio, V., Ianni Palarchio, A. et al. (1998). Enhanced effects of amoxycillin/clavulanate compared with amoxycillin and clavulanate alone on the susceptibility to immunodefenses of a penicillin-resistant strain of Streptococcus pneumoniae. Drugs Under Experimental and Clinical Research 24, 173-84.
24. Soriano, F., Ponte, C., Nieto, E. et al. (1996). Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy 38, 227-36.
25. Beale, A. S., Faulds, E., Hurn, S. E. et al. (1991). Comparative activities of amoxycillin, amoxycillin/clavulanate and tetracycline against Chlamydia trachomatis in cell culture and in an experimental mouse pneumonitis. Journal of Antimicrobial Chemotherapy 27, 627-38.
26. Verbist, L. (1983). Antimicrobial activity of Augmentin in vitro. In Augmentin: Clavulanate-Potentiated Amoxycillin. Proceedings of the First Symposium - 1980. (Rolinson, G. N. & Watson, A., Eds), pp. 42-6. Excerpta Medica, Amsterdam, The Netherlands.
27. Hammond, B. F. & Rams, T. E. (1996). Synergy of amoxicillin and clavulanate on beta-lactamase positive and negative periodontal pathogens. Journal of Dental Research 75, 429.
28. Greenwood, D. (1980). A type of interaction between clavulanate and other beta-lactam antimicrobials distinct from the beta-lactamase inhibition effect. In Augmentin: Clavulanate-Potentiated Amoxycillin. Proceedings of the First Symposium - 1980. (Rolinson, G. N. & Watson, A., Eds), pp. 80-3. Excerpta Medica, Amsterdam, The Netherlands.
29. Greenwood, D., O'Grady, F. & Baker, P. (1979). An in vitro evaluation of clavulanate, a potent, broad-spectrum beta-lactamase inhibitor. Journal of Antimicrobial Chemotherapy 5, 539-47.
30. Cuffini, A. M., De Renzi, G., Tullio, V. et al. (1996). Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanate. Drugs Under Experimental and Clinical Research 22, 9-15.
31. Gomez-Lus, M. L., Aguilar, L., Martin, M. et al. (1997). Intracellular and extracellular killing of a penicillin-resistant, serotype-9 strain of Streptococcus pneumoniae by polymorphonuclear leucocytes in the presence of sub-inhibitory concentrations of clavulanic acid. Journal of Antimicrobial Chemotherapy 40, 142-4.
32. Martin, M., Gomez-Lus, M. L., Aguilar, L. et al. (1997). Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against Streptococcus pneumoniae. European Journal of Clinical Microbiology and Infectious Diseases 16, 512-6.
33. Pascual, A., Martinez Martinez, L., Aragon, J. et al. (1989). Effect of amoxycillin and clavulanic acid, alone and in combination, on human polymorphonuclear leukocyte function against Staphylococcus aureus. European Journal of Clinical Microbiology and Infectious Diseases 8, 277-81.
34. Cuffini, A. M., Tullio, V., Giacchino, F. et al. (2001). Improved phagocyte response by co-amoxiclav in renal transplant recipients. Transplantation 71, 575-7.
35. Cuffini, A. M., Tullio, V., Giacchino, F. et al. (2001). Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients. American Journal of Kidney Diseases 37, 1253-9.
36. Reato, G., Cuffini, A. M., Tullio, V. et al. (1999). Co-amoxiclav affects cytokine production by human polymorphonuclear cells. Journal of Antimicrobial Chemotherapy 43, 715-8.
37. Hofbauer, R., Moser, D., Gmeiner, B. et al. (1999). Amoxycillin/clavulanic acid combinations increase transmigration of leucocytes through endothelial cell monolayers: endothelial cells play a key role. Journal of Antimicrobial Chemotherapy 44, 465-9.
38. Andes, D. & Craig, W. A. (1998). In vivo activities of amoxicillin and amoxicillin/clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrobial Agents and Chemotherapy 42, 2375-9.
39. Gisby, J., Wightman, B. J. & Beale, A. S. (1991). Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. Antimicrobial Agents and Chemotherapy 35, 831-6.
40. Smith, G. M., Slocombe, B., Abbott, K. H. et al. (1998). Activity of amoxicillin/clavulanate against penicillin-resistant Streptococcus pneumoniae in an experimental respiratory infection model in rats. Antimicrobial Agents and Chemotherapy 42, 813-7.
41. Yokota, T. (1989). Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin. APMIS 5, Suppl., 9-16.
42. Mainardi, J. L., Gutmann, L., Acar, J. F. et al. (1995). Synergistic effect of amoxicillin and cefotaxime against Enterococcurs faecalis. Antimicrobial Agents and Chemotherapy 39, 1984-7 [Published erratum appears in Antimicrobial Agents and Chemotherapy 39, 2835].
43. Kadioglu, A., Gingles, N. A., Grattan, K. et al. (2000). Host cellular immune response to pneumococcal lung infection in mice. Infection and Immunity 68, 492-501.